Evidence for Efficacy of Antidepressants for Pain Is Limited
In 11 comparisons, antidepressants were efficacious, but they were inefficacious or evidence was inconclusive for 31 comparisons
In 11 comparisons, antidepressants were efficacious, but they were inefficacious or evidence was inconclusive for 31 comparisons
The table provided is a review of notable updates that occurred in January 2023 for investigational products in development.
Exxua (previously named Travivo) is a novel oral serotonin 1A receptor agonist.
The updated recommendations include both nonpharmacologic and pharmacologic interventions for adults in the acute phase of MDD.
Period prevalence of all antipsychotic prescriptions increased 3.3 percent per year from 2000 to 2019
The table provided is a review of notable updates that occurred in December 2022 for investigational products in development.
Treatment-resistant depression episodes tied to more psychiatric comorbid conditions, health care utilization, self-harm, and all-cause mortality
The approval was based on data from 2 trials in adults who met DSM-IV-TR or DSM-5 criteria for MDD and had an inadequate response to 1 to 3 courses of prior antidepressant therapy.
The designation is supported by data from 3 clinical studies.